Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

UFS student makes breakthrough in the application of nanorobots
2005-04-21

A student from the University of the Free State (UFS) has made a ground-breaking discovery in the field of microbiology by uncovering a series of new compounds that may in future be used to lubricate man-made nanorobots.

Mr Olihile Sebolai, a full-time student at the UFS’s Department of Microbial- Biochemical and Food Biotechnology, made this discovery while working on his M Sc-study on yeast.

With this discovery Mr Sebolai will also be awarded six prestigious prizes during this week’s autumn graduation ceremony at the UFS.  This university has recognised this exceptional achievement as a build-up to the celebration of national Science and Technology week next month.     

Mr Sebolai’s dissertation on the yeast genus Saccharomycopsis Schionning has been published in an accredited international journal of repute. 

“Words cannot describe how excited I am. I never expected to receive such recognition for my studies.  I am humbled by all of this,” said Mr Sebolai.

The Lipid Biotechnology Group at the UFS recently discovered that some yeasts produce their own water-propelled capsules in which they are transported.  These capsules have different shapes and resemble among others miniature flying saucers, hats with razor sharp brims etc.  “In order to function properly, parts of the capsules are oiled with prehistoric lubricants – lubricants that are produced by yeasts and that probably existed for many millions of years as yeasts developed,” said Mr Sebolai.  

According to Mr Sebolai these capsules are so small that approximately 300 can be fitted into the full-stop at the end of a sentence and are therefore invisible to the naked eye.

“With my studies I discovered many new compounds that resemble these prehistoric lubricants.  These lubricants may in future be used to lubricate man-made nanorobots and are similar in size compared to yeast capsules,” said Mr Sebolai.  The nanorobots are used to perform tasks in places that are invisible to the naked eye and could one day be used, among others, to clean up human arteries.

Mr Sebolai has been interested in the subject of Micro technology since he was at RT Mokgopa High School in Thaba ‘Nchu.  “I was specifically interested in the many possible applications the subject has – in the industry, as well as in medicine,” said Mr Sebolai. 

His next goal is to successfully complete his Ph D-degree.

The prizes that will be awarded to Mr Sebolai this week include:

Best Magister student at the UFS (Senate medal and prize);

Best Magister student in the Faculty of Natural and Agricultural Science and Dean’s medal at the same faculty;

The Andries Brink – Sasol-prize for the best M Sc dissertation in Microbiology;

The JP van der Walt prize for best M Sc dissertation in yeast science;

The Chris Small prize for an outstanding Master’s dissertation; and

Honorary colours awarded by the UFS Student Representative Council

Media release

Issued by:                     Lacea Loader

                                    Media Representative

                                    Tel:  (051) 401-2584

                                    Cell:  083 645 2454

                                    E-mail:  loaderl.stg@mail.uovs.ac.za

20 April 2005

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept